# 2026年1月2日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 靶向 STK17B：解锁骨髓瘤中的铁死亡机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41477748)
**期刊：** Blood
**PMID：** 41477748
**DOI：** 10.1182/blood.2025031316

### 第一部分 原文与翻译

**英文原标题：** Targeting STK17B: unlocking ferroptosis in myeloma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究聚焦于STK17B在骨髓瘤铁死亡中的关键作用，可能通过分子靶向策略揭示恶性浆细胞死亡的新机制。尽管目前暂无摘要可供详阅，但从标题可推测，研究强调铁死亡通路在肿瘤代谢脆弱性中的潜在价值。此方向或为难治性多发性骨髓瘤开辟新的治疗思路，具有较高的创新性。然而，需进一步观察其机制验证与临床可转化性。

---

## 2. REC8-黏连蛋白在减数分裂早期优先定位于受转录抑制因子 BEND2 调控的基因启动子上

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476252)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41476252
**DOI：** 10.1093/gpbjnl/qzaf138

### 第一部分 原文与翻译

**英文原标题：** REC8-Cohesin Preferentially Localizes to Promoters of Genes that are Regulated by Transcription Suppressor BEND2 During Early Meiosis.

> **英文摘要：**
> Cohesin plays critical roles in chromatin organization and transcription regulation. REC8 is a meiosis-specific cohesin subunit and is essential for homologous chromosome synapsis, recombination, and segregation. However, little is known about the relationship between the dynamic genome-wide distribution of cohesin and transcription regulation during meiotic initiation. In this study, we report that REC8-cohesin is preferentially localized to open promoter regions of genes involved in spermatogonial differentiation and meiosis at early meiosis from preleptonema to zygonema. Genomic localization of REC8-cohesin is changed by the gene knockout of the transcriptional suppressor BEND2. We also find that REC8 is able to interact with mitotic cyclin CCNA2, that the CCNA2 expression is extended to leptonema in Bend2 knockout mice, and that the meiotic cells of Bend2 knockout mice do not exit the mitotic cell cycle completely. We further found that a large number of genes are commonly bound by BEND2, STRA8, MEIOSIN, and REC8-cohesin. Our study has therefore revealed that genes with open promoters are bound by meiotic cohesin and transcription factors coordinately to facilitate chromatin reorganization and transcription regulation leading to the switch from a mitotic cell cycle to a meiotic one at the initiation stage of meiosis.

> **中文摘要：**
> 黏连蛋白在染色质组织和转录调控中起关键作用。REC8 是一种减数分裂特异性的黏连蛋白亚基，对同源染色体的联会、重组及分离至关重要。然而，目前对减数分裂起始阶段黏连蛋白在全基因组动态分布与转录调控之间的关系知之甚少。在本研究中，我们报告了 REC8-黏连蛋白在减数分裂早期（从前细线期到偶线期）优先定位于参与精原细胞分化和减数分裂的基因开放启动子区域。REC8-黏连蛋白的基因组定位会因转录抑制因子 BEND2 的基因敲除而改变。我们还发现，REC8 能与有丝分裂周期蛋白 CCNA2 相互作用，在 Bend2 敲除小鼠中，CCNA2 的表达延伸至细线期，并且这些小鼠的减数分裂细胞未能完全退出有丝分裂细胞周期。进一步的研究表明，大量基因同时被 BEND2、STRA8、MEIOSIN 和 REC8-黏连蛋白所结合。因此，我们的研究揭示，具有开放启动子的基因可被减数分裂黏连蛋白及转录因子协同结合，以促进染色质重组和转录调控，从而在减数分裂起始阶段实现从有丝分裂周期向减数分裂周期的转换。

### 第二部分 AI 大师评价

本研究通过整合基因组定位和分子互作分析，揭示了减数分裂特异性黏连蛋白 REC8 与转录抑制因子 BEND2 之间的关键关联。研究发现，REC8 优先定位于开放启动子区，并通过与 BEND2 及多种减数分裂调控因子共结合，协调染色质结构与转录调控，从而实现细胞周期从有丝分裂向减数分裂的转变。结果深化了对减数分裂起始阶段基因调控网络的认识，突显了黏连蛋白在染色质重塑中的功能创新。研究的局限在于主要基于小鼠模型，未来需进一步验证保守性及机制细节。

---

## 3. 染色质调控因子突变的肿瘤与更高的突变负荷及改进的免疫检查点治疗反应相关。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476223)
**期刊：** Clinical epigenetics
**PMID：** 41476223
**DOI：** 10.1186/s13148-025-02038-0

### 第一部分 原文与翻译

**英文原标题：** Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy.

> **英文摘要：**
> In recent years, it has been demonstrated that many of the pervasive genetic defects throughout cancerogenesis occur in genes encoding chromatin regulators (CRs). We analyzed the distribution and characteristics of well-studied CRs across tens of thousands of tumor samples. Our analysis revealed that tumors with mutations in CRs are associated with high tumor mutational burden (TMB). The co-occurrence of mutations in multiple CRs was linked with a further increase in TMB. Given that TMB may predict the clinical response to immune checkpoint inhibitor (ICI) treatment, we investigated the relationship between mutations in CRs and ICI response. We found that patients harboring mutations in CRs exhibited improved responses to ICI treatment, comparable to those with deficiencies in canonical DNA repair pathways. Overall, this study uncovered significant relationships between mutations in chromatin regulators and critical features of cancer, underscoring the need for further functional and clinical studies.

> **中文摘要：**
> 近年来的研究表明，在癌症发生过程中，许多普遍存在的基因缺陷出现在编码染色质调控因子（CRs）的基因中。我们分析了数万个肿瘤样本中已深入研究的CRs的分布及特征。分析结果显示，具有CRs突变的肿瘤与较高的肿瘤突变负荷（TMB）相关。多个CRs突变的共存与TMB的进一步升高有关。鉴于TMB可能预测免疫检查点抑制剂（ICI）治疗的临床反应，我们还探究了CRs突变与ICI反应之间的关系。结果发现，携带CRs突变的患者对ICI治疗的反应有所改善，其效果与经典DNA修复通路缺陷患者相当。总体而言，本研究揭示了染色质调控因子突变与癌症关键特征之间的重要关联，强调了进一步开展功能和临床研究的必要性。

### 第二部分 AI 大师评价

本研究系统分析了染色质调控因子（CRs）突变在不同肿瘤中的分布特征及其与突变负荷和免疫治疗反应的关系。结果显示CRs突变不仅与更高的肿瘤突变负荷相关，还可预测对免疫检查点抑制剂的更好反应。这提示CRs可能作为新的免疫治疗生物标志物，帮助优化受益人群的筛选。研究创新性在于从表观遗传调控层面揭示免疫治疗反应机制，但其局限可能在于对因果关系和不同肿瘤类型差异的进一步验证仍需实验数据支持。

---

## 4. 多模态成像绘制免疫治疗分布图作为胶质瘤预测性标志物的研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476211)
**期刊：** Neuro-oncology
**PMID：** 41476211
**DOI：** 10.1093/neuonc/noaf295

### 第一部分 原文与翻译

**英文原标题：** Multimodality mapping of immunotherapy distribution as a predictive marker in glioma.

> **英文摘要：**
> BACKGROUND: Scarce T cell infiltration, immunosuppressive tumor-associated macrophages and ineffective drug delivery drive glioma progression and limit treatment efficacy. Mapping immunotherapy distribution by multimodality imaging might be a biomarker that could aid tumor monitoring and guide therapy development.
> 
> METHODS: To assess drug delivery, we developed a MRI-lightsheet microscopy platform (MR-LSM) to monitor immunotherapy at the cellular level in two immunocompetent glioma models (Gl261, SB28). The atezolizumab (PD-L1 inhibitor) subgroup of the multicenter N2M2/NOA20 trial in MGMT unmethylated GBM patients was assessed by CNN analysis and correlated to progression free survival.
> 
> RESULTS: In contrast to the conventional Gl261 glioma model, SB28 gliomas are characterized by poor immunogenicity and resistance to Toll-like receptor (TLR) 7 targeted therapy delivered by CDNP-R848 nanoparticles. SB28 resistance is driven by microvascular pathology, vasogenic edema and drug off-targeting to peritumoral edema and white matter tracts. Vascular endothelial growth factor (VEGF) inhibition in conjunction with irradiation and dual immunotherapy (DIR) targeting innate (CDNP-R848) and adaptive immunity (anti-CTLA-4) breaks resistance, increases survival and reverses drug off-targeting. Mechanistically, tumor control is orchestrated by vascular normalization, enhanced CD8+ T cell influx and a proinflammatory shift of myeloid cells along with strong IL-12/IL-13 upregulation. In a translational analysis of the multicenter N2M2/NOA20 trial we validate that edema and microvascular pathology are associated with poor prognosis in glioblastoma patients treated with checkpoint immunotherapy and that patients without edema have increased PFS.
> 
> CONCLUSIONS: We develop a customizable imaging platform to map drug delivery to glioma with broad applicability in neuroscience and neurooncology.

> **中文摘要：**
> 背景：T 细胞浸润稀少、肿瘤相关巨噬细胞的免疫抑制作用以及药物递送效率低下共同驱动胶质瘤进展并限制治疗效果。通过多模态影像绘制免疫治疗的分布图，可能成为一种有助于肿瘤监测和指导治疗开发的生物标志物。
> 
> 方法：为评估药物递送情况，我们开发了一种 MRI-光片显微镜平台（MR-LSM），可在两个免疫健全的胶质瘤模型（Gl261、SB28）中在细胞水平监测免疫治疗。我们还通过 CNN 分析评估了多中心 N2M2/NOA20 试验中 MGMT 未甲基化 GBM 患者亚组（接受 PD-L1 抑制剂阿替利珠单抗治疗）的数据，并将其与无进展生存期相关联。
> 
> 结果：与常规的 Gl261 胶质瘤模型相比，SB28 胶质瘤表现出低免疫原性，并对通过 CDNP-R848 纳米颗粒递送的 Toll 样受体 7（TLR7）靶向治疗具有耐药性。SB28 的耐药机制源于微血管病变、血管源性水肿以及药物在肿瘤周围水肿区和白质束中的非靶向分布。使用血管内皮生长因子（VEGF）抑制剂联合放射治疗及双重免疫治疗（DIR，靶向先天免疫的 CDNP-R848 与靶向适应性免疫的抗 CTLA-4 抗体）可打破这种耐药性，延长生存并逆转药物的非靶向分布。从机制上看，肿瘤控制由血管正常化、CD8+ T 细胞浸润增强以及髓系细胞向促炎性表型转变（伴随 IL-12/IL-13 显著上调）共同驱动。多中心 N2M2/NOA20 试验的转化分析进一步验证了：水肿与微血管病变与接受检查点免疫治疗的胶质母细胞瘤患者的不良预后相关，而无水肿患者则具有更长的无进展生存期。
> 
> 结论：我们开发了一种可定制的影像平台，用于绘制胶质瘤的药物递送图谱，具有在神经科学和神经肿瘤学领域的广泛应用潜力。

### 第二部分 AI 大师评价

本研究通过创新性地建立 MRI-光片显微镜多模态成像平台，实现了对免疫治疗药物在胶质瘤中的细胞级分布监测，并结合临床试验数据揭示了微血管病变与水肿对免疫治疗效果的不良影响。研究发现 VEGF 抑制联合放疗及双重免疫治疗可有效逆转耐药性并改善预后，展示了多层次机制验证的科学严谨性。其创新点在于从成像技术到临床转化的系统性整合，但需要进一步验证该平台在人体实时动态监测中的适用性。

---

## 5. 从癌症组织病理学生成跨模态基因表达可提升多模态人工智能预测性能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476170)
**期刊：** Nature communications
**PMID：** 41476170
**DOI：** 10.1038/s41467-025-66961-9

### 第一部分 原文与翻译

**英文原标题：** Generating crossmodal gene expression from cancer histopathology improves multimodal AI predictions.

> **英文摘要：**
> Emerging research has highlighted that artificial intelligence-based multimodal fusion of digital pathology and transcriptomic features can improve cancer diagnosis (grading/subtyping) and prognosis (survival risk) prediction. However, such direct fusion is impractical in clinical settings, where histopathology remains the gold standard and transcriptomic tests are rarely requested in public healthcare. We experiment on two publicly available multimodal datasets, The Cancer Genomic Atlas and the Clinical Proteomic Tumor Analysis Consortium, spanning four independent cohorts: glioma-glioblastoma, renal, uterine, and breast, and observe significant performance gains in gradation and risk estimation (p-value  <  0.05) when incorporating synthesized transcriptomic data with WSIs. Also, predictions using synthesized features were statistically close to those obtained with real transcriptomic data (p-value  >  0.05), consistently across cohorts. Here we show that with our diffusion based crossmodal generative AI model, PathGen, gene expressions synthesized from digital histopathology jointly predict cancer grading and patient survival risk with high accuracy (state-of-the-art performance), certainty (through conformal coverage guarantee) and interpretability (through distributed co-attention maps). PathGen code is available on GitHub at https://github.com/Samiran-Dey/PathGen for open use.

> **中文摘要：**
> 新兴研究强调，基于人工智能的数字病理学与转录组特征的多模态融合，可改进癌症的诊断（分级/分型）及预后（生存风险）预测。然而，这种直接融合在临床环境中并不现实，因为组织病理学仍是金标准，而转录组检测在公共医疗中极少被要求。我们在两个公开的多模态数据集上进行实验，即癌症基因组图谱（TCGA）和临床蛋白质组肿瘤分析联盟（CPTAC），涵盖了四个独立队列：胶质瘤–胶质母细胞瘤、肾癌、子宫癌和乳腺癌。当将合成的转录组数据与全视野切片（WSI）结合时，我们观察到分级与风险评估性能显著提升（p值 < 0.05）。此外，使用合成特征的预测结果在统计上与真实转录组数据所得结果接近（p值 > 0.05），且在各队列中一致。我们展示了通过基于扩散模型的跨模态生成式人工智能模型 PathGen，从数字病理切片合成的基因表达数据能够以高准确性（达到当前最先进性能）、高确定性（通过一致性覆盖保证）及高可解释性（通过分布式协同注意力图）共同预测癌症分级及患者生存风险。PathGen 源代码已在 GitHub（https://github.com/Samiran-Dey/PathGen）公开提供。

### 第二部分 AI 大师评价

该研究旨在通过扩散模型 PathGen，从癌症数字病理图像生成跨模态的转录组特征，以改进癌症诊断和预后预测。作者验证了在 TCGA 与 CPTAC 多模态数据集上的有效性，显示合成的转录组数据能显著提升分级与风险预测性能，且接近真实转录组结果。其创新点在于跨模态生成式 AI 模型，在保证预测准确性、可解释性与不确定性校准的同时，克服了临床中转录组数据缺乏的限制。尽管仍需在真实临床环境中验证其通用性，但该工作为病理与多组学融合提供了可行的新路径。

---

## 6. 伊诺妥珠单抗奥佐米星在复发/难治性B细胞急性淋巴细胞白血病中的真实世界疗效。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476164)
**期刊：** Blood cancer journal
**PMID：** 41476164
**DOI：** 10.1038/s41408-025-01448-w

### 第一部分 原文与翻译

**英文原标题：** Real world outcomes with the use of Inotuzumab Ozogamicin in relapsed/refractory B cell acute lymphoblastic leukemia.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可供参考。

### 第二部分 AI 大师评价

本研究基于真实世界数据，探讨了伊诺妥珠单抗奥佐米星在复发或难治性B细胞急性淋巴细胞白血病患者中的临床应用效果。尽管缺少摘要，但推测研究关注治疗有效性及安全性指标，旨在评估该抗体药物偶联物在常规临床实践中的疗效表现。该工作有助于弥合临床试验与真实治疗环境之间的差距，但研究设计、样本代表性与长期随访信息可能仍有限。

---

## 7. 老年胰岛素抗性骨的磷酸蛋白组学研究揭示 P70S6K 对 AFF4 的磷酸化作为基因特异性转录调控因子。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476161)
**期刊：** Nature communications
**PMID：** 41476161
**DOI：** 10.1038/s41467-025-68106-4

### 第一部分 原文与翻译

**英文原标题：** Phosphoproteomics of aged insulin-resistant bone identifies P70S6K phosphorylation of AFF4 as a gene-specific transcriptional regulator.

> **英文摘要：**
> Insulin action on the skeleton is essential for bone development and whole-body energy metabolism, however a global view of signaling in this tissue is lacking. Furthermore, whether there are signaling differences that drive the gene-specific activation under insulin-resistant (IR) or ageing conditions is unknown. Here, we perform a phosphoproteomic analysis of insulin signaling in the bones of young, lean, insulin-sensitive versus old, obese, IR mice revealing a rewiring of phosphorylation. We target dysregulated phosphoproteins in a zebrafish functional genomic screen of bone development and mineralization revealing candidates important for skeletal formation. One of these is ALF Transcription Elongation Factor 4 (AFF4), the core scaffold of the Super Elongation Complex and we show that phosphorylation of S831 on AFF4 is an insulin-dependent substrate of P70S6K and attenuated in aged, IR bone. Phosphorylation of S831 is defective in IR osteoblasts and associated with reduced transcriptional elongation at discrete locations in the genome. Mechanistically, we show phosphorylation of S831 increases recruitment of chromatin remodelers, ENL/AF9 to crotonylated histone via the YEATS domain, and promotes gene-specific activation. Our analysis identifies regulators of insulin action on the skeleton, further uncovering a mechanism of IR via locus-specific changes in transcriptional elongation and gene activation.

> **中文摘要：**
> 胰岛素在骨骼中的作用对于骨骼发育以及全身能量代谢至关重要，然而，目前仍缺乏关于该组织信号传导的整体视角。此外，尚不清楚在胰岛素抗性（IR）或衰老条件下，是否存在驱动基因特异性激活的信号差异。本研究通过对年轻、瘦型、胰岛素敏感小鼠与年老、肥胖、胰岛素抗性小鼠骨组织的胰岛素信号通路进行磷酸蛋白组学分析，揭示了磷酸化网络的重构。研究者针对在骨发育与矿化相关的斑马鱼功能基因组筛选中发现的异常磷酸化蛋白进行验证，确定了对骨骼形成至关重要的候选分子。其中之一为延伸因子 AFF4（ALF 转录延伸因子 4），它是超级延伸复合物的核心支架。研究表明，AFF4 上的 S831 位点是 P70S6K 的胰岛素依赖性底物，并在老年和胰岛素抗性骨中磷酸化水平减弱。S831 的磷酸化缺陷出现在胰岛素抗性成骨细胞中，并与基因组特定位置的转录延伸减少相关。从机制上看，S831 的磷酸化可促进染色质重塑因子 ENL/AF9 通过 YEATS 结构域结合至丁酰化组蛋白，从而增强基因特异性激活。该研究识别出调控骨骼中胰岛素作用的新因子，并进一步揭示了通过位点特异性转录延伸及基因激活变化介导胰岛素抗性的分子机制。

### 第二部分 AI 大师评价

该研究利用磷酸蛋白组学手段系统分析了胰岛素信号在不同年龄及胰岛素敏感状态下的小鼠骨组织中的变化，揭示了磷酸化通路在衰老与胰岛素抗性过程中的重构。通过动物模型与功能筛选，研究确定 AFF4 的 S831 位点为 P70S6K 介导的关键磷酸化位点，并阐明其在转录延伸及基因特异性调控中的作用。该工作不仅丰富了对骨骼胰岛素信号调控网络的理解，也为探索代谢性骨疾病的分子机制提供了新方向。其创新性体现在跨物种整合分析及信号传导与表观遗传调控的结合，但仍需进一步验证在人类组织中的生理意义。

---

## 8. 脑膜瘤细胞重编程及其与微环境的相互作用是脑侵袭的基础。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476144)
**期刊：** Neuro-oncology
**PMID：** 41476144
**DOI：** 10.1093/neuonc/noaf292

### 第一部分 原文与翻译

**英文原标题：** Meningioma cell reprogramming and microenvironment interactions underlie brain invasion.

> **英文摘要：**
> BACKGROUND: Meningioma brain invasion encumbers surgical resection and increases the risk of tumor recurrence, but the molecular mechanisms underlying this process are poorly understood.
> 
> METHODS: To identify molecular and cellular features of brain-invasive meningiomas, we (1) analyzed bulk RNA sequencing data from 199 meningiomas, including 33 brain-invasive tumors, (2) analyzed patient-matched single-cell RNA sequencing data of spatially mapped meningioma samples from the tumor core or brain-tumor interface (BTI), and (3) performed spatial transcriptomic sequencing of brain-invasive meningioma samples. Multiplexed immunofluorescence (IF) was used to validate bioinformatic spatial expression patterns. Functional interactions between meningioma cells and neurons were studied in meningioma/neuron co-cultures using confocal microscopy, multi-electrode array recordings, and live cell calcium imaging.
> 
> RESULTS: Transcriptomic analyses showed conserved enrichment of TGM2, S100A11, ZYX, and PDGFRA at the BTI across bulk, single-cell, and spatial RNA sequencing datasets. The expression of these genes at the BTI was confirmed using multiplexed IF, and single-cell bioinformatic and microscopy analyses further demonstrated enrichment of macrophages at the BTI. Co-culture assays showed neuronal hyperexcitability and increased proliferation of meningioma cells, suggesting functional communication between meningioma cells and the tumor microenvironment may contribute to meningioma growth in cases with brain invasion.
> 
> CONCLUSIONS: Meningioma brain invasion is defined by molecular remodeling of tumor cells and functional interactions within the tumor microenvironment.

> **中文摘要：**
> 背景：脑膜瘤的脑侵袭会增加手术切除的难度并提高肿瘤复发风险，但其潜在的分子机制仍然知之甚少。
> 
> 方法：为识别脑侵袭性脑膜瘤的分子及细胞特征，我们：（1）分析了199例脑膜瘤的整体RNA测序数据，其中包括33例脑侵袭性肿瘤；（2）分析了患者配对的单细胞RNA测序数据，这些数据来源于肿瘤核心区和脑-肿瘤界面（BTI）空间定位的脑膜瘤样本；（3）对脑侵袭性脑膜瘤样本进行了空间转录组测序。采用多重免疫荧光（IF）验证生物信息学分析得到的空间表达模式。脑膜瘤细胞与神经元之间的功能相互作用通过脑膜瘤/神经元共培养体系进行研究，并结合共聚焦显微成像、多电极阵列记录及活细胞钙成像技术进行分析。
> 
> 结果：转录组学分析显示，在整体、单细胞及空间RNA测序数据集中，TGM2、S100A11、ZYX和PDGFRA在BTI处均呈保守性富集。多重IF证实了这些基因在BTI的表达；单细胞生物信息学分析及显微镜观察进一步显示BTI处巨噬细胞的富集。共培养实验表明，神经元表现出高兴奋性，脑膜瘤细胞增殖增强，提示脑膜瘤细胞与肿瘤微环境之间的功能性交流可能促进脑侵袭病例中的肿瘤生长。
> 
> 结论：脑膜瘤的脑侵袭由肿瘤细胞的分子重塑及其在肿瘤微环境中的功能性相互作用所定义。

### 第二部分 AI 大师评价

本研究旨在揭示脑膜瘤脑侵袭的分子和微环境机制。作者结合整体RNA测序、单细胞RNA测序及空间转录组学，系统描绘了脑-肿瘤界面的分子特征，并通过免疫荧光与功能性共培养实验验证关键发现。研究发现TGM2、S100A11、ZYX及PDGFRA等基因在脑侵袭界面富集，同时伴随巨噬细胞的聚集及神经元高兴奋性变化，提示微环境与肿瘤细胞存在促侵袭性的双向交流。该研究在方法整合与空间层面机制揭示上具有显著创新性，但未来仍需进一步验证这些信号通路在临床中的可干预性。

---

## 9. 既往治疗对输血依赖性、ESA复发或难治/不适用的低风险骨髓增生异常综合征患者伊美司特临床活性的影响

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476142)
**期刊：** Blood cancer journal
**PMID：** 41476142
**DOI：** 10.1038/s41408-025-01444-0

### 第一部分 原文与翻译

**英文原标题：** Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究旨在探讨既往治疗经历如何影响伊美司特在输血依赖性、ESA复发或耐药/不适用的低风险骨髓增生异常综合征（LR-MDS）患者中的临床疗效。研究聚焦于既往治疗模式对药物反应和患者转归的潜在调节作用，可能为临床精准分层提供依据。尽管尚无摘要披露，但可预期该研究强调了伊美司特在复杂既往治疗背景下的应用价值，其结果或为MDS治疗策略优化提供重要线索。

---

## 10. 基于长读长测序数据的体细胞结构变异检测基准与评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476128)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41476128
**DOI：** 10.1093/gpbjnl/qzaf139

### 第一部分 原文与翻译

**英文原标题：** Benchmark and Evaluation for Somatic Structural Variants Detection with Long-read Sequencing Data.

> **英文摘要：**
> Somatic structural variations (somatic SVs) are hallmarks of tumors, but their comprehensive detection remains technically challenging. Long-read sequencing (LRS) technology, which generates reads spanning large-scale SVs and their flanking sequences, enables a wide range of prospects for somatic SV detection. However, existing LRS-based somatic SV detection algorithms and pipelines exhibit variable performance that has not been systematically characterized. In this study, we conducted a rigorous evaluation of 51 LRS-based somatic SV detection strategies, integrating 3 reference genomes, 2 aligners, 5 SV callers, and 5 processing methods tailored for SV callers. We use both simulated datasets and empirical data from HCC1395/HCC1395BL cell lines sequenced on Oxford Nanopore (ONT) and Pacific Biosciences (PacBio) platforms for technical assessment. Our findings highlight the need for further refinement of specialized somatic SV detection tools, as no single strategy consistently outperforms across all scenarios. Workflows based on germline SV callers exhibit a high false-positive rate, which cannot be mitigated by increasing sequencing depth or tumor purity. Furthermore, challenges persist in detecting insertions, genomic tandem repeat regions, and ultra-long SVs. We delineate technical bottlenecks in current somatic SV detection approaches and provide recommendations for their further advancement. Additionally, we offer suggestions for selecting specific tools in different application scenarios. This work offers a comprehensive benchmark for somatic SV detection and valuable insights for future LRS-based tools development and methodological improvements.

> **中文摘要：**
> 体细胞结构变异（somatic SVs）是肿瘤的标志性特征，但其全面检测仍然面临技术挑战。长读长测序（LRS）技术能够生成跨越大尺度结构变异及其侧翼序列的测序读长，为体细胞结构变异的检测提供了广阔前景。然而，现有基于LRS的体细胞结构变异检测算法和分析流程表现差异较大，且尚未得到系统性表征。在本研究中，我们对51种基于LRS的体细胞结构变异检测策略进行了严格评估，整合了3个参考基因组、2种比对工具、5个结构变异检测器以及5种针对检测器优化的处理方法。我们使用了既包括模拟数据，又包括来源于HCC1395/HCC1395BL细胞系在牛津纳米孔（ONT）和太平洋生物（PacBio）平台上测序的实测数据进行技术评估。研究结果强调了进一步优化专门的体细胞结构变异检测工具的必要性，因为目前没有单一策略能在所有场景下持续表现优越。基于生殖系变异检测器的分析流程显示出较高的假阳性率，而这一问题无法通过提高测序深度或肿瘤纯度来缓解。此外，在检测插入变异、基因组串联重复区域及超长结构变异时仍然面临挑战。我们明确了当前体细胞结构变异检测方法中的技术瓶颈，并提供了改进建议。此外，还针对不同应用场景提出了特定工具的选择建议。本研究为体细胞结构变异检测提供了一个全面的基准，并为未来基于LRS的工具开发与方法学改进提供了重要启示。

### 第二部分 AI 大师评价

本研究系统评估了51种基于长读长测序的体细胞结构变异检测策略，通过整合不同参考基因组、比对工具及变异检测方法，构建了目前最全面的性能基准。研究揭示了现有算法在检测插入、串联重复和超长变异方面的关键瓶颈，并指出生殖系检测器在体细胞应用中存在较高假阳性率。作者的工作不仅为工具选择与优化提供了实证指导，也为未来LRS技术在肿瘤基因组变异研究中的方法学改进奠定了基础。

---

## 11. VITA-GBM：通过EPIC-0502介导的HIF1α降解克服贝伐单抗耐药并与TMZ在胶质母细胞瘤中协同作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476110)
**期刊：** Neuro-oncology
**PMID：** 41476110
**DOI：** 10.1093/neuonc/noaf293

### 第一部分 原文与翻译

**英文原标题：** VITA-GBM: EPIC-0502-Driven HIF1α Degradation Overcomes Bevacizumab Resistance and Synergizes with TMZ in Glioblastoma.

> **英文摘要：**
> BACKGROUND: Glioblastoma (GBM) is characterized by extensive tissue hypoxia. This hypoxic microenvironment drives chemoresistance and promotes aberrant vascularization, critically limiting the efficacy of temozolomide (TMZ) and bevacizumab (BEV). Here, we report EPIC-0502, a novel small-molecule competitive antagonist that inhibits hypoxia signaling while sensitizing GBM to both TMZ and BEV.
> 
> METHODS: EPIC-0502 was identified through molecular dynamics simulation. Its target blocking effect was validated via non-targeted metabolomics, stable isotope tracing-based metabolic flux analysis, and pull-down assays. The mechanisms underlying EPIC-0502 activity were elucidated by Western Blot (WB), Co-Immunoprecipitation (Co-IP), ELISA, Seahorse assays, and Immunofluorescence (IF). The sensitizing effects of EPIC-0502 on TMZ and BEV were evaluated in orthotopic GBM models.
> 
> RESULTS: EPIC-0502 inhibited α-ketoglutarate (α-KG) to succinate conversion, depleting cytoplasmic succinate levels and inhibiting phosphoglycerate kinase 1 (PGK1) succinylation and phosphorylation, which significantly attenuated glycolysis. Furthermore, EPIC-0502 destabilized HIF1α by promoting hydroxylation-dependent ubiquitination, while impairing its transcriptional activity. Through HIF1α degradation, EPIC-0502 enhanced GBM sensitivity to TMZ via E2F1 downregulation and reversed hypoxia-induced vascular endothelial growth factor A (VEGFA) overexpression, potentiating the antiangiogenic efficacy of BEV. Collectively, these actions enable EPIC-0502 to synergistically enhance the therapeutic efficacy of TMZ/BEV combination.
> 
> CONCLUSION: Based on EPIC-0502-driven HIF1α degradation that overcomes BEV resistance and synergizes with TMZ, we propose the novel VITA-GBM regimen comprising: Vascular targeting (BEV), Inhibition of hypoxia signaling (EPIC-0502), TMZ chemotherapy, and Alignment of synergistic mechanisms. This strategy enhances the efficacy of first-line therapies and provides a promising approach to improve overall survival in GBM patients.

> **中文摘要：**
> 背景：胶质母细胞瘤（GBM）的特征是广泛的组织缺氧。这种缺氧的微环境驱动化疗耐药并促进异常血管生成，从而严重限制替莫唑胺（TMZ）和贝伐单抗（BEV）的疗效。在此，我们报告EPIC-0502，这是一种新型小分子竞争性拮抗剂，可抑制缺氧信号并使GBM对TMZ和BEV均更为敏感。
> 
> 方法：通过分子动力学模拟筛选出EPIC-0502。其靶点阻断作用通过非靶向代谢组学、稳定同位素示踪的代谢流分析及pull-down实验得到验证。EPIC-0502的作用机制通过Western Blot（WB）、共免疫沉淀（Co-IP）、ELISA、Seahorse检测及免疫荧光（IF）加以阐明。采用原位GBM模型评估EPIC-0502对TMZ和BEV的增敏作用。
> 
> 结果：EPIC-0502抑制α-酮戊二酸（α-KG）向琥珀酸的转化，降低细胞质琥珀酸水平，并抑制磷酸甘油酸激酶1（PGK1）的琥珀酰化与磷酸化，从而显著削弱糖酵解。此外，EPIC-0502通过促进羟基化依赖性泛素化使HIF1α失稳，同时削弱其转录活性。通过HIF1α的降解，EPIC-0502通过下调E2F1增强GBM对TMZ的敏感性，并逆转缺氧诱导的血管内皮生长因子A（VEGFA）过表达，从而增强BEV的抗血管生成效应。总体而言，这些作用使EPIC-0502能够协同增强TMZ和BEV联合治疗的疗效。
> 
> 结论：基于EPIC-0502介导的HIF1α降解可克服BEV耐药并与TMZ产生协同效应的发现，我们提出新的VITA-GBM方案，包括：血管靶向（BEV）、缺氧信号抑制（EPIC-0502）、TMZ化疗及协同机制耦合。这一策略可提高一线治疗的疗效，并为改善GBM患者的总体生存率提供有前景的方法。

### 第二部分 AI 大师评价

该研究针对GBM缺氧导致的TMZ和BEV耐药难题，开发了小分子拮抗剂EPIC-0502。作者通过多组学与分子生物学手段揭示其作用机制：促进HIF1α降解、抑制糖酵解和血管生成，从而显著增强TMZ及BEV的疗效。提出的VITA-GBM方案整合了血管靶向、缺氧信号抑制及化疗协同，具有较强的临床转化潜力。研究创新性高，但后续仍需验证长期安全性与临床效果。

---

## 12. 对胱氨酸限制应激的适应赋予胰腺导管腺癌可靶向的脂质代谢脆弱性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476081)
**期刊：** Nature communications
**PMID：** 41476081
**DOI：** 10.1038/s41467-025-68099-0

### 第一部分 原文与翻译

**英文原标题：** Adaptation to cystine limitation stress confers a targetable lipid metabolism vulnerability in pancreatic ductal adenocarcinoma.

> **英文摘要：**
> Cystine/cysteine is critical for antioxidant response and sulfur metabolism in cancer cells and is one of the most depleted amino acids in the microenvironment of pancreatic ductal adenocarcinoma (PDAC). The effects of cystine limitation stress (CLS) on PDAC progression are poorly understood. Here we report that adaptation to CLS (CLSA) promotes PDAC cell proliferation and tumor growth through translational upregulation of the oxidative pentose phosphate pathway (OxPPP). OxPPP activates the de novo synthesis of nucleotides and fatty acids to support tumor growth. On the other hand, CLSA-mediated lipidomic reprogramming depends on triacylglycerides synthesis and lipid droplet formation to mitigate lipotoxicity. Through drug screening, we identify lomitapide as an inhibitor of CLSA PDAC tumor growth and a potent sensitizer of chemotherapy. Lomitapide inhibits triacylglycerides synthesis to interfere with CLSA and chemotherapy-induced lipidomic reprogramming. Taken together, we demonstrate that CLSA promotes PDAC tumor growth through metabolic reprogramming and lomitapide could be used to target the dysregulated lipid metabolism in PDAC.

> **中文摘要：**
> 胱氨酸/半胱氨酸在癌细胞的抗氧化应答和硫代谢中起关键作用，并且是胰腺导管腺癌（PDAC）肿瘤微环境中最为匮乏的氨基酸之一。关于胱氨酸限制应激（CLS）对PDAC进展的影响目前了解甚少。在本研究中，我们报告了PDAC细胞对CLS的适应（CLSA）可通过翻译水平上调氧化戊糖磷酸途径（OxPPP），从而促进细胞增殖和肿瘤生长。OxPPP可激活核苷酸和脂肪酸的从头合成，以支持肿瘤生长。另一方面，CLSA介导的脂质组重编程依赖于三酰甘油的合成及脂滴的形成，以缓解脂毒性。通过药物筛选，我们鉴定出洛米他派（lomitapide）是一种可抑制CLSA型PDAC肿瘤生长并增强化疗敏感性的药物。洛米他派通过抑制三酰甘油合成，干扰CLSA及化疗诱导的脂质组重编程。综上所述，我们揭示了CLSA通过代谢重编程促进PDAC肿瘤生长，而洛米他派可用于靶向PDAC中失调的脂质代谢。

### 第二部分 AI 大师评价

本研究聚焦于胱氨酸限制应激下胰腺导管腺癌的代谢适应机制，揭示了肿瘤通过上调氧化戊糖磷酸途径及脂质组重编程实现生长优势。通过药物筛选发现洛米他派能有效抑制三酰甘油合成并增强化疗敏感性，显示出潜在的靶向治疗价值。研究创新性在于将营养应激与代谢重编程联系起来，并提出了代谢脆弱性的可药物化靶点。局限性在于目前主要为实验层面验证，临床应用仍需进一步研究。

---

## 13. 甲硫氨酸限制通过表观遗传性抑制 TGF-β-Smad3-Hoxc8/P-TEFb 轴缓解肾脏纤维化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476080)
**期刊：** Nature communications
**PMID：** 41476080
**DOI：** 10.1038/s41467-025-68061-0

### 第一部分 原文与翻译

**英文原标题：** Methionine restriction alleviates kidney fibrosis through epigenetic repression of the TGF-β-Smad3-Hoxc8/P-TEFb axis.

> **英文摘要：**
> Low-protein diets can mitigate renal fibrosis, yet the critical amino acids responsible for this benefit and its underlying mechanism remain unclear. Using exclusively male mice throughout this study, we screen 15 amino acid-restricted diets in a unilateral ureteral obstruction model and identify methionine restriction (MetR) as the most effective intervention. Integrating transcriptomic and cistromic analyses identify Hoxc8 as a central pro-fibrotic transcription factor downstream of TGF-β-Smad3 signaling. Hoxc8 reinforces its own expression and drives fibrotic gene programs through recruitment of the P-TEFb transcriptional elongation complex. HOXC8 is elevated in fibrotic human kidneys, and fibroblast-specific Hoxc8 deletion protects mice from renal fibrosis. MetR suppresses this pro-fibrotic circuit by reducing active histone marks at the Hoxc8 locus, thereby attenuating Hoxc8-dependent transcription. Together, these findings identify the TGF-β-Smad3-Hoxc8/P-TEFb axis as a key driver of renal fibrosis and highlight MetR as a promising therapeutic strategy.

> **中文摘要：**
> 低蛋白饮食可减轻肾脏纤维化，但引起这一益处的关键氨基酸及其潜在机制尚不清楚。本研究中，研究者在全程使用雄性小鼠的单侧输尿管梗阻模型中筛选了15种限制性氨基酸饮食，并确定甲硫氨酸限制（MetR）是最有效的干预措施。整合转录组学与结合组分析发现，Hoxc8 是位于 TGF-β-Smad3 信号通路下游的核心促纤维化转录因子。Hoxc8 通过募集转录延伸复合物 P-TEFb 来增强自身表达并驱动纤维化基因程序。在人类纤维化肾脏中，HOXC8 水平升高，而成纤维细胞特异性敲除 Hoxc8 可保护小鼠免受肾脏纤维化。MetR 通过减少 Hoxc8 位点的活性组蛋白修饰，抑制这一促纤维化环路，从而减弱 Hoxc8 依赖的转录活性。综上所述，这些研究结果表明 TGF-β-Smad3-Hoxc8/P-TEFb 轴是肾脏纤维化的关键驱动因子，并指出甲硫氨酸限制是一种具有前景的治疗策略。

### 第二部分 AI 大师评价

本研究系统解析了饮食氨基酸组成对肾脏纤维化的影响，通过多组学整合揭示甲硫氨酸限制可通过表观遗传机制抑制 TGF-β-Smad3-Hoxc8/P-TEFb 促纤维化通路。研究设计严谨，明确了 Hoxc8 在纤维化进程中的关键转录调控作用。该发现创新性地揭示了代谢与表观遗传交互调控肾纤维化的新机制，为代谢性干预提供了潜在治疗方向。其局限性在于仅采用雄性小鼠模型，尚需进一步验证其性别依赖性及临床可行性。

---

## 14. 复发/难治性多发性骨髓瘤患者接受西利塔卡布基因自体CAR‑T治疗后免疫效应细胞相关迟发性神经毒性的临床过程、风险因素及干预策略研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476076)
**期刊：** Blood cancer journal
**PMID：** 41476076
**DOI：** 10.1038/s41408-025-01441-3

### 第一部分 原文与翻译

**英文原标题：** Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma.

> **英文摘要：**
> We examined the clinical course and risk factors for late onset neurotoxicities, including nerve palsies (IEC-NP) and parkinsonism (IEC-PKS), in patients with relapsed/refractory multiple myeloma (RRMM) treated with ciltacabtagene autoleucel (cilta-cel) in standard-of-care practice (SOC). Among 235 RRMM patients who received cilta-cel, 15 (6.4%) developed IEC-NP and 9 (3.8%) developed IEC-PKS with one patient developing both. Pre-infusion, patients with age >75 years, bone marrow plasma cells ≥20%, or involved free light chain ≥20 mg/dL had increased odds of IEC-PKS. Post-infusion, patients who developed ICANS, received higher cumulative steroid doses or received >1 dose of tocilizumab also had increased odds of IEC-PKS. High peak absolute lymphocyte count (ALCpeak) was a statistically significant predictor on univariate and multivariate analysis for IEC-NP and IEC-PKS. ALC ≥ 3 × 10/L was identified as a meaningful threshold (AUC = 0.838) to predict for late onset neurotoxicity. An ALC ≥ 3 × 10/L conferred a positive predictive value for delayed neurotoxicity of 31% vs a negative predictive value of 98% in patients with ALC < 3 × 10/L. All IEC-NP patients received steroid +/- IVIG; 87% had complete resolution of their cranial neuropathies (median 57 days). Four patients with IEC-PKS received cyclophosphamide (1.5-2 g/m) within 1-13 days of symptom onset and all had observable symptom improvement within 1-2 days.

> **中文摘要：**
> 我们研究了在标准临床实践中，接受西利塔卡布基因自体CAR‑T细胞治疗（cilta‑cel）的复发/难治性多发性骨髓瘤（RRMM）患者中，迟发性神经毒性（包括神经麻痹〔IEC‑NP〕和帕金森综合征样表现〔IEC‑PKS〕）的临床过程与风险因素。235例接受cilta‑cel治疗的RRMM患者中，15例（6.4%）出现IEC‑NP，9例（3.8%）出现IEC‑PKS，其中1例同时发生两种情况。输注前，年龄>75岁、骨髓浆细胞比例≥20%或相关游离轻链浓度≥20 mg/dL的患者，发生IEC‑PKS的风险增加。输注后，出现ICANS、接受较高累积糖皮质激素剂量或使用托珠单抗次数>1次的患者，IEC‑PKS风险亦升高。单变量和多变量分析显示，高峰绝对淋巴细胞计数（ALCpeak）是预测IEC‑NP及IEC‑PKS的统计学显著指标。ALC ≥ 3 × 10/L被确定为预测迟发性神经毒性的有意义阈值（AUC = 0.838）。当ALC ≥ 3 × 10/L时，迟发性神经毒性的阳性预测值为31%，而ALC < 3 × 10/L时阴性预测值为98%。所有IEC‑NP患者均接受了糖皮质激素±免疫球蛋白治疗；其中87%颅神经病变完全缓解，中位时间为57天。4例IEC‑PKS患者在症状出现后1–13天内接受1.5–2 g/m²环磷酰胺治疗，均在1–2天内观察到症状改善。

### 第二部分 AI 大师评价

本研究系统分析了接受西利塔卡布基因CAR‑T治疗的复发/难治性多发性骨髓瘤患者中迟发性神经毒性的临床特征与危险因素。研究发现，年龄大、骨髓肿瘤负荷高及输注后高ALC水平与神经毒性密切相关，且ALC可作为较有价值的预测指标。治疗方面，糖皮质激素和环磷酰胺在症状缓解中显示出潜在作用。研究的创新性在于揭示了晚发性免疫效应细胞相关神经毒性的量化风险阈值，但仍受样本规模及真实世界异质性限制。

---

## 15. 一种集成透明超声换能器和光纤扫描器的手持光声显微探头

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476066)
**期刊：** Nature communications
**PMID：** 41476066
**DOI：** 10.1038/s41467-025-68148-8

### 第一部分 原文与翻译

**英文原标题：** A handheld photoacoustic microscopic probe integrating a transparent ultrasound transducer and a fiber scanner.

> **英文摘要：**
> Photoacoustic microscopy (PAM) has been widely used in biomedical studies to provide high-resolution 3D anatomical, functional, and molecular images of living subjects. While handheld PAM systems have been proposed to extend its applicability, it has proved challenging to achieve a compact device that combines fast imaging with high spatial resolution and signal to noise ratio. Here we demonstrate a handheld PAM probe integrating a fiber scanner and high-frequency transparent ultrasound transducer (TUT), called hPAM-TUT. The compact system (measuring 17 mm in diameter, with a 90 mm long rigid body) achieves high lateral and axial resolutions (7 and 47 μm, respectively), has a 2.6 mm diameter field of view, and delivers a single volumetric image in 1.5 s. In living rats, we used hPAM-TUT to visualize various abdominal organs, and in mice we used it to observe epinephrine-induced vascular changes and image the anatomy and functioning of lymphatic vessels after injection of Evans blue dye. Additionally, we successfully delineated murine vascular networks in early metastatic tumors. This handheld PAM probe shows promise for both clinical and research applications in such fields as dermatology, oncology, and intraoperative imaging.

> **中文摘要：**
> 光声显微成像（PAM）已被广泛应用于生物医学研究，可为活体对象提供高分辨率的三维解剖、功能及分子图像。尽管已经提出了手持式 PAM 系统以扩展其应用范围，但要实现兼具快速成像、高空间分辨率和高信噪比的紧凑设备仍具挑战性。在本研究中，我们展示了一种集成光纤扫描器和高频透明超声换能器（TUT）的手持式 PAM 探头，称为 hPAM-TUT。该紧凑系统（直径 17 毫米，刚性主体长度 90 毫米）实现了高横向和轴向分辨率（分别为 7 微米和 47 微米），具有 2.6 毫米直径的成像视野，并能在 1.5 秒内获得单个体积图像。在活体大鼠中，我们使用 hPAM-TUT 可视化了多种腹部器官；在小鼠实验中，我们用它观察肾上腺素诱导的血管变化，并在注射伊文思蓝染料后成像淋巴管的解剖结构和功能。此外，我们成功描绘了小鼠早期转移性肿瘤中的血管网络。该手持式 PAM 探头在皮肤科、肿瘤学及术中成像等领域的临床与科研应用中展现出良好前景。

### 第二部分 AI 大师评价

本研究旨在开发一款集透明超声换能器与光纤扫描技术于一体的手持光声显微探头，以实现高速、高分辨率的生物成像。研究团队设计的 hPAM-TUT 系统结构紧凑，具备亚百微米级分辨率，并能够快速获取三维图像。通过在大鼠和小鼠中的实验，验证了该系统在复杂活体组织中对血管、淋巴与肿瘤结构的成像能力。创新点在于将透明超声换能技术与光声显微集成，为临床即时成像提供了新的可行路径；局限性在于其成像深度与扫描范围仍需进一步提升以满足广泛临床场景的需求。

---

## 16. CYP8B1通过抑制u-STAT1核转位从而抑制PAK4转录，进而抑制肝细胞癌的进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476054)
**期刊：** Cell death & disease
**PMID：** 41476054
**DOI：** 10.1038/s41419-025-08393-3

### 第一部分 原文与翻译

**英文原标题：** CYP8B1 inhibits hepatocellular carcinoma progression by repressing PAK4 transcription through inhibition of nuclear translocation of u-STAT1.

> **英文摘要：**
> Primary and secondary bile acid (BA) levels are elevated in patients with hepatocellular carcinoma (HCC). BAs are important signaling molecules that regulate CYP8B1 expression by targeting nuclear and membrane receptors. In this study, we aimed to determine the function of CYP8B1 in HCC. Examination of HCC tissue and bioinformatic analysis revealed that CYP8B1 expression is downregulated in HCC tissues and is associated with good prognosis. Cholic acid promoted Huh7 cell proliferation and migration by inhibiting CYP8B1 expression. Both in vitro and in vivo, CYP8B1 inhibited the proliferation, invasion, and migration of HCC cells. Nanopore long-read RNA-sequencing analysis identified PAK4 as a potential target of CYP8B1, and the MAPK pathway was associated with CYP8B1 expression. CYP8B1 inhibited PAK4 expression and Raf/MEK/ERK phosphorylation. Tissue microarray analysis also verified a strong correlation between CYP8B1 and PAK4 expression. In vitro Cell Counting Kit 8 assays and in vivo orthotopic liver tumor model analyses showed that CYP8B1 restores sorafenib sensitivity in resistant HC, suggesting its potential as a therapeutic target. IP-MS of CYP8B1 and transcription factor prediction of PAK4 revealed STAT1 as a potential transcription factor for PAK4, which may directly bind to CYP8B1. Chromatin immunoprecipitation confirmed that u-STAT1 directly binds to the PAK4 promoter, not p-STAT1. Overall, CYP8B1 binds to u-STAT1 in the cytoplasm, reducing the translocation of u-STAT1 from the cytoplasm to the nucleus, thereby inhibiting the transcription of PAK4 and ultimately inhibiting the phosphorylation of Raf/MEK/ERK. Our findings indicate that the CYP8B1/PAK4 axis is important in HCC progression and elucidate the mechanism by which BAs promote HCC. Thus, CYP8B1 is a potential therapeutic target for the clinical treatment of HCC.

> **中文摘要：**
> 原发性和次级胆汁酸（BA）水平在肝细胞癌（HCC）患者中升高。胆汁酸是调控CYP8B1表达的重要信号分子，其作用靶点包括核受体和膜受体。本研究旨在阐明CYP8B1在HCC中的作用。通过对HCC组织的检测及生物信息学分析发现，CYP8B1在HCC组织中的表达下调，并与良好预后相关。胆酸通过抑制CYP8B1表达促进Huh7细胞的增殖和迁移。体内外实验均表明，CYP8B1可抑制HCC细胞的增殖、侵袭和迁移。基于Nanopore长读长RNA测序分析，确定PAK4是CYP8B1的潜在靶基因，且MAPK信号通路与CYP8B1表达相关。CYP8B1可抑制PAK4表达及Raf/MEK/ERK的磷酸化。组织芯片分析进一步验证了CYP8B1与PAK4表达之间存在显著相关性。体外CCK-8检测及体内原位肝癌模型分析显示，CYP8B1可恢复耐药HCC对索拉非尼的敏感性，提示其具有潜在的治疗靶点价值。通过CYP8B1的免共沉淀质谱（IP-MS）及PAK4的转录因子预测，发现STAT1可能是PAK4的转录因子，并可直接与CYP8B1结合。染色质免疫沉淀实验证实，u-STAT1可直接结合于PAK4启动子，而p-STAT1则不结合。总体而言，CYP8B1在胞质中与u-STAT1结合，减少u-STAT1从胞质向细胞核的转位，从而抑制PAK4转录，最终抑制Raf/MEK/ERK的磷酸化。我们的研究结果表明，CYP8B1/PAK4轴在HCC进展中具有重要意义，并阐释了胆汁酸促进HCC的机制。因此，CYP8B1可能成为HCC临床治疗的潜在靶点。

### 第二部分 AI 大师评价

该研究系统阐明了CYP8B1在肝细胞癌中的抑癌作用机制。研究团队结合组织学、生物信息学、体内外功能实验及转录调控分析，揭示CYP8B1通过结合并抑制u-STAT1核转位，从而下调PAK4转录和MAPK通路活性。该工作首次明确了CYP8B1/PAK4轴在HCC进展中的关键作用，为胆汁酸调控肝癌的分子机制提供了新见解。其创新性体现在整合多组学与机制验证的深入探索，同时为新型靶向治疗提供潜在方向，但仍需在更大患者队列中进一步验证。

---

## 17. 质子泵抑制剂的使用与儿童炎症性肠病风险的关联

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41475980)
**期刊：** Gut
**PMID：** 41475980
**DOI：** 10.1136/gutjnl-2025-337345

### 第一部分 原文与翻译

**英文原标题：** Proton pump inhibitors use and risk of inflammatory bowel disease in children.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

该研究旨在探讨儿童使用质子泵抑制剂（PPI）与炎症性肠病（IBD）发生风险之间的关系。虽然摘要未公开，但从标题可推测研究可能采用了流行病学或队列设计，分析药物使用与疾病发生的关联性。此类研究有助于评估PPI在儿童人群中的安全性，并为临床合理用药提供证据基础。其创新性体现在关注儿童特殊人群，但可能受限于观察性研究设计和潜在混杂因素。

---

## 18. 通过转录性诱导同源重组修复，靶向GSK3β/NFATc1亚型可克服胰腺癌的治疗耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41475977)
**期刊：** Gut
**PMID：** 41475977
**DOI：** 10.1136/gutjnl-2025-336227

### 第一部分 原文与翻译

**英文原标题：** GSK3β/NFATc1 subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair.

> **英文摘要：**
> BACKGROUND: The efficacy of pharmacological glycogen synthase kinase-3β (GSK3β) inhibition is currently being investigated in unselected cohorts of metastatic pancreatic ductal adenocarcinoma (PDAC). Here, we sought to determine the clinical significance of nuclear GSK3β accumulation in patients with resectable PDAC.
> 
> OBJECTIVE: This study aimed to explore the therapeutic potential and underlying mechanisms of GSK3β pathway disruption in PDAC with enriched nuclear GSK3β levels.
> 
> DESIGN: We investigated the activation and function of GSK3β and its downstream transcription factor NFATc1 in tumour recurrence, growth and resistance using human PDAC tissues, patient-derived organoids and tumour cells, PDAC explants, cell lines and murine models. GSK3β signalling was disrupted using genetic and pharmacological approaches. Live-cell imaging, proliferation, homologous recombination (HR) repair and comet assays, messenger RNA sequencing and chromatin immunoprecipitation were used to explore GSK3β-NFATc1 signalling-mediated target gene regulation in DNA repair, growth and resistance.
> 
> RESULTS: Nuclear GSK3β accumulates in a subset of resected PDAC and promotes proliferation and DNA repair through NFATc1. The GSK3β/NFATc1 subtype accounts for 14% of resected PDAC and is associated with rapid tumour recurrence and poor survival. The GSK3β-NFATc1 signalling pathway contributes to cisplatin resistance by inducing BRCA genes transcription, which facilitates HR-mediated DNA double-strand breaks (DSBs) repair. Disruption of the GSK3β-NFATc1 axis impairs HR-driven DSB repair, increasing cisplatin sensitivity in vitro and in preclinical PDAC models.
> 
> CONCLUSION: We have identified a highly aggressive GSK3β/NFATc1 subtype that predicts early recurrence, poor survival and cisplatin resistance in PDAC. This subtype reveals new treatment vulnerabilities suggesting that patients with PDAC may benefit from stratification-based tailored treatment strategies.

> **中文摘要：**
> 背景：药理性抑制糖原合酶激酶-3β（GSK3β）的疗效目前正在未分选的转移性胰腺导管腺癌（PDAC）队列中进行研究。本研究旨在确定可切除PDAC患者中核内GSK3β聚集的临床意义。
> 
> 研究目的：本研究旨在探索在核内GSK3β水平升高的PDAC中破坏GSK3β通路的治疗潜力及其潜在机制。
> 
> 研究设计：我们通过使用人类PDAC组织、患者来源的类器官和肿瘤细胞、PDAC离体标本、细胞系及小鼠模型，研究了GSK3β及其下游转录因子NFATc1在肿瘤复发、生长与耐药中的活化与功能。通过遗传学和药理学方法破坏GSK3β信号通路。采用活细胞成像、细胞增殖、同源重组（HR）修复与彗星实验、信使RNA测序及染色质免疫沉淀等技术，探索GSK3β-NFATc1信号介导的DNA修复、生长与耐药相关靶基因的调控。
> 
> 结果：核内GSK3β在部分切除的PDAC样本中积聚，并通过NFATc1促进细胞增殖和DNA修复。GSK3β/NFATc1亚型占切除PDAC的14%，并与肿瘤快速复发和较差生存相关。GSK3β-NFATc1信号通路通过诱导BRCA基因的转录促进HR介导的DNA双链断裂（DSB）修复，从而促成顺铂耐药。破坏GSK3β-NFATc1轴可损伤HR驱动的DSB修复，增加PDAC细胞在体外及临床前模型中的顺铂敏感性。
> 
> 结论：我们鉴定出一种高度侵袭性的GSK3β/NFATc1亚型，可预测PDAC的早期复发、预后不良及顺铂耐药性。该亚型揭示了新的治疗脆弱点，提示PDAC患者可能从基于分型的个体化治疗策略中受益。

### 第二部分 AI 大师评价

该研究聚焦于胰腺导管腺癌中GSK3β/NFATc1信号轴的作用，揭示核内GSK3β聚集亚型与肿瘤复发及顺铂耐药密切相关。研究者通过组织样本、类器官、细胞及动物模型的多层验证，系统阐明了此信号通路通过调控BRCA介导的DNA同源重组修复而促进耐药。其创新性在于定义了一种新的生物学亚型并提出潜在的分层治疗思路，然而在临床推广前仍需更大型验证研究。

---

## 19. 单细胞与空间转录组分析揭示突变型结直肠癌中的免疫抑制空间生态位

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41475845)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41475845
**DOI：** 10.1136/jitc-2025-013763

### 第一部分 原文与翻译

**英文原标题：** Single-cell and spatial transcriptome profiling identifies the immunosuppressive spatial niche in -mutant colorectal cancer.

> **英文摘要：**
> BACKGROUND: is one of the most frequently mutated genes in colorectal cancer (CRC) and plays a crucial role in tumorigenesis, progression, immune evasion, and treatment resistance. The pronounced heterogeneity within -mutant CRC highlights the urgent need for more precise and personalized therapeutic approaches.
> 
> METHODS: To investigate this heterogeneity, we employed single-cell RNA sequencing and spatial transcriptomics to comprehensively characterize the tumor microenvironment of -mutant CRC. Data preprocessing and clustering were performed using Scanpy. Spatial cell-type deconvolution was conducted via Cell2location, whereas intercellular communication and spatial dependencies were analyzed using CellChat, MISTy, and stLearn.
> 
> RESULTS: Our analyses revealed that -mutant tumor epithelial cells recruit Mono_ monocytes via the MDK_SDC4 signaling axis. Concurrently, surrounding Fib_ fibroblasts secrete collagen, which interacts with integrin receptors on -mutant epithelial cells and contributes to the exclusion of lymphocyte infiltration.
> 
> CONCLUSION: These cellular components collaboratively established an immunosuppressive spatial niche. These findings offer novel theoretical insights and potential targets for the development of immunoregulatory strategies tailored to -mutant CRC.

> **中文摘要：**
> 背景： 是结直肠癌（CRC）中最常见的突变基因之一，在肿瘤发生、进展、免疫逃逸和治疗耐药中发挥关键作用。突变型结直肠癌内显著的异质性凸显了开发更精准、个体化治疗策略的紧迫需求。
> 
> 方法： 为探究这种异质性，我们采用单细胞RNA测序与空间转录组学，对突变型结直肠癌的肿瘤微环境进行全面表征。数据预处理与聚类分析通过Scanpy完成；空间细胞类型去卷积由Cell2location执行，而细胞间通信及空间依赖关系的分析则利用CellChat、MISTy和stLearn进行。
> 
> 结果： 我们的分析结果显示，突变型肿瘤上皮细胞通过MDK_SDC4信号轴招募Mono_单核细胞。同时，周围的Fib_成纤维细胞分泌胶原蛋白，与突变型上皮细胞表面的整合素受体相互作用，从而促成了淋巴细胞浸润的排斥。
> 
> 结论： 这些细胞组分协同构建了一个免疫抑制性空间生态位。这些发现为开发针对突变型结直肠癌的免疫调控策略提供了新的理论见解与潜在靶点。

### 第二部分 AI 大师评价

该研究旨在通过单细胞RNA测序与空间转录组学的整合揭示突变型结直肠癌的免疫抑制性微环境特征。研究者系统阐明了肿瘤上皮细胞、单核细胞与成纤维细胞之间的信号互作及其空间分布特征。结果发现特定信号通路和细胞相互作用共同塑造了免疫排斥性的肿瘤生态位。该研究创新性地将多模态空间分析工具结合使用，为理解突变驱动的免疫微环境异质性提供了新思路，但由于研究依赖模型推断，其机制验证仍需进一步实验支持。

---

## 20. PD-1 抑制剂相关免疫性血小板减少症的机制性洞见：结合纵向转录组学分析的病例报告

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41475844)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41475844
**DOI：** 10.1136/jitc-2025-013108

### 第一部分 原文与翻译

**英文原标题：** Mechanistic insights into PD-1 inhibitor-associated immune thrombocytopenia: a case report integrating longitudinal transcriptomic profiling.

> **英文摘要：**
> Immune checkpoint inhibitors (ICIs) have significantly improved survival outcomes in patients with advanced malignancies. However, their association with immune thrombocytopenia (ITP) poses a critical risk of severe hemorrhage and necessitates treatment discontinuation. The precise molecular mechanisms underlying ICI-associated ITP remain largely unclear, critically impeding the development of predictive biomarkers and targeted therapeutic strategies. Here, we present a case report of an elderly patient with stage IV gastric adenocarcinoma who developed recurrent ITP following programmed death receptor-1 (PD-1) inhibitor serplulimab, trastuzumab and chemotherapy. Notably, longitudinal peripheral blood mononuclear cell samples were collected and subjected to transcriptomic profiling before and after two distinct ITP episodes: the initial occurrence and a recurrence triggered by PD-1 inhibitor rechallenge, providing matched time-resolved data for mechanistic analysis. Our findings demonstrate that ICIs-induced ITP involves a dual pathogenic mechanism combining immune-mediated platelet destruction and intrinsic megakaryopoietic impairment providing a novel conceptual framework for understanding this immunotherapy complication. And this represents the first prospective longitudinal investigation combining serial biospecimen collection with transcriptomic profiling (RNA sequencing) to elucidate mechanisms underlying ICIs-induced ITP.

> **中文摘要：**
> 免疫检查点抑制剂（ICIs）显著改善了晚期恶性肿瘤患者的生存结局。然而，其与免疫性血小板减少症（ITP）的关联带来了严重出血的关键风险，并常常导致治疗中断。ICIs 相关 ITP 的精确分子机制仍大多不明，这显著阻碍了预测性生物标志物和靶向治疗策略的开发。本文报道了一例老年 IV 期胃腺癌患者，在接受程序性死亡受体-1（PD-1）抑制剂 serplulimab、曲妥珠单抗及化疗后，出现复发性 ITP。值得注意的是，研究者在两次不同 ITP 发作前后（首次发生及 PD-1 抑制剂再挑战引起的复发）采集了纵向外周血单个核细胞样本，并进行了转录组分析，从而获得了匹配时间分辨的机制性数据。研究结果显示，ICIs 诱导的 ITP 涉及免疫介导的血小板破坏及内在造血巨核生成障碍的双重致病机制，为理解此类免疫治疗并发症提供了新的概念框架。此外，该研究是首个结合连续生物样本采集与转录组（RNA 测序）分析的前瞻性纵向研究，用以阐明 ICIs 诱导 ITP 的潜在机制。

### 第二部分 AI 大师评价

本研究通过结合纵向转录组学监测与病例观察，解析了 PD-1 抑制剂相关免疫性血小板减少症的双重致病机制。研究独特地同时揭示了免疫介导的血小板破坏和巨核生成障碍，为理解免疫检查点抑制剂相关血液毒性提供了新的生物学框架。方法上采用动态样本收集与 RNA 测序的整合分析，具创新性和探索性。尽管仅为单病例研究，样本量受限，但其机制性发现为未来预测与干预提供了重要线索。

---

## 21. 可植入人工淋巴结促进体内新抗原特异性T细胞的快速生成与扩增以增强抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41475843)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41475843
**DOI：** 10.1136/jitc-2025-013043

### 第一部分 原文与翻译

**英文原标题：** Implantable artificial lymph node enables rapid in vivo neoantigen-specific T-cell generation and expansion for improving antitumor immunity.

> **英文摘要：**
> BACKGROUND: Tumor neoantigen vaccines typically require multiple prime-boost immunizations over several weeks or even months to elicit sufficient neoantigen-specific T-cell responses, which greatly limits their effectiveness against rapidly progressing cancers, such as hepatocellular carcinoma.
> 
> METHODS: Here, we developed a functionalized alginate scaffold for T-cell activation as an artificial lymph node (FAST-LN) to rapidly and efficiently generate tumor neoantigen-specific T cells in vivo. The FAST-LN consists of an alginate scaffold crosslinked with calcium ions and hyaluronic acids conjugated with anti-TIM-3 (T cell immunoglobulin and mucin domain-containing protein-3) antibodies, then incorporates tumor neoantigen-encoding adenoviral vaccines, dendritic cells (DCs), and various cytokines (C-C motif chemokine ligand 21 (CCL21), interleukin (IL)-2, IL-4, and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)) that maintain DC maturation and recruit T cells for antigen presentation.
> 
> RESULTS: This design facilitates efficient DC-T cell interactions within FAST-LN, enabling rapid generation of neoantigen-specific T cells for antitumor responses. In vivo antitumor studies demonstrated superior therapeutic efficacy of FAST-LN over traditional vaccines in mouse tumor models. Mechanistically, FAST-LN significantly enhanced tumor infiltration of CD8 T cells, Th1 cells and macrophages, orchestrating robust antitumor responses.
> 
> CONCLUSIONS: Our results demonstrate that implantable FAST-LN rapidly induces tumor neoantigen-specific T cells in vivo, offering a promising strategy for neoantigen-based cancer immunotherapy.

> **中文摘要：**
> 背景：肿瘤新抗原疫苗通常需要在数周甚至数月内进行多次初免和加强免疫，以诱导足够的针对新抗原的T细胞反应，这极大地限制了其在如肝细胞癌等快速进展癌症中的疗效。
> 
> 方法：本研究开发了一种用于T细胞激活的功能化海藻酸钠支架，作为人工淋巴结（FAST-LN），以便在体内快速高效地生成肿瘤新抗原特异性T细胞。FAST-LN由钙离子交联的海藻酸钠支架和与抗TIM-3（T细胞免疫球蛋白及粘蛋白结构域蛋白3）抗体偶联的透明质酸组成，并载入编码肿瘤新抗原的腺病毒疫苗、树突状细胞（DCs）和多种细胞因子（包括C-C基序趋化因子配体21（CCL21）、白细胞介素（IL）-2、IL-4以及粒细胞-巨噬细胞集落刺激因子（GM-CSF）），以维持DC成熟并招募T细胞进行抗原呈递。
> 
> 结果：该设计促进了FAST-LN内高效的DC-T细胞相互作用，从而实现了新抗原特异性T细胞的快速生成以产生抗肿瘤反应。体内抗肿瘤研究显示，FAST-LN在小鼠肿瘤模型中的治疗效果优于传统疫苗。从机制上看，FAST-LN显著增强了CD8 T细胞、Th1细胞及巨噬细胞对肿瘤的浸润，从而协调了强有力的抗肿瘤免疫反应。
> 
> 结论：本研究结果表明，可植入的FAST-LN能够在体内快速诱导肿瘤新抗原特异性T细胞，为基于新抗原的癌症免疫治疗提供了一种极具前景的策略。

### 第二部分 AI 大师评价

该研究旨在通过可植入的人工淋巴结（FAST-LN）实现体内快速高效的新抗原特异性T细胞生成，以突破传统新抗原疫苗反应慢、疗效有限的瓶颈。作者采用功能化海藻酸钠支架装载DC细胞、新抗原疫苗及多种因子，实现了模拟淋巴微环境的人工免疫活化系统。动物实验验证了其较传统疫苗更强的抗肿瘤效应，尤其在促进CD8 T细胞和Th1细胞浸润方面具有优势。该研究的创新在于工程化免疫微环境快速诱导体内应答，但临床可行性、长期免疫记忆及安全性仍需进一步验证。

---

## 22. 嵌合抗原受体树突状细胞在癌前模型中抑制黑色素瘤生长。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41475842)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41475842
**DOI：** 10.1136/jitc-2025-013040

### 第一部分 原文与翻译

**英文原标题：** Chimeric antigen receptor dendritic cells suppress melanoma growth in preclinical cancer models.

> **英文摘要：**
> BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy has been successful for the treatment of hematological cancers but less effective against solid tumors, a phenomenon that results from the immunosuppressive nature of the tumor microenvironment. As a strategy to improve the treatment of solid tumors, we applied CAR therapy to dendritic cells (DCs) to generate CAR-DCs. The CAR targeted the human epidermal growth factor receptor 2 (HER2) which is overexpressed in breast cancer to defeat the immunosuppressive nature of the tumor microenvironment.
> 
> METHODS: CAR-DCs were generated by lentiviral vector transduction of SAMHD1 knock-out murine bone marrow-derived DCs. The vectors coexpressed CD40L and a soluble form of programmed cell death 1 (PD-1), a checkpoint inhibitor. To increase the durability of CAR-DCs, a gene encoding the cytokine GM-CSF was introduced into the CAR vector. The CAR-DCs were injected into mice bearing B16.HER2 melanoma tumors. Tumor growth was measured, and T cell functionality was determined by IFNγ expression and in vitro cytolytic assay.
> 
> RESULTS: CAR-DCs suppressed the growth of B16.HER2 tumors and induced the proliferation and activation of tumor-infiltrating cytolytic CD8+T cells. The PD-1 checkpoint inhibitor further augmented the antitumor response and prevented T cell exhaustion. Vectored expression of GM-CSF increased the durability of the antitumor response.
> 
> CONCLUSIONS: CAR-DCs could be an effective strategy for therapies against solid tumors that should be further explored. The approach relies on the antigen-presenting ability of DCs and their role in T cell activation and can be coupled with checkpoint inhibition in place of monoclonal antibody treatment.

> **中文摘要：**
> 背景：嵌合抗原受体（CAR）T细胞治疗在血液系统肿瘤的治疗中取得了成功，但对实体瘤的疗效较差，这主要归因于肿瘤微环境的免疫抑制特性。为改善实体瘤的治疗效果，我们将CAR技术应用于树突状细胞（DC），生成CAR-DCs。该CAR靶向人表皮生长因子受体2（HER2），该受体在乳腺癌中过度表达，用以克服肿瘤微环境的免疫抑制特性。
> 
> 方法：通过慢病毒载体转导SAMHD1敲除小鼠骨髓来源的DCs，生成CAR-DCs。载体共表达CD40L及可溶性程序性细胞死亡受体1（PD-1），后者是一种检查点抑制因子。为增强CAR-DCs的持久性，将编码细胞因子GM-CSF的基因引入CAR载体中。随后将CAR-DCs注射入携带B16.HER2黑色素瘤的鼠体内。通过测量肿瘤生长以及检测干扰素γ（IFNγ）表达和体外细胞溶解实验来评估T细胞功能。
> 
> 结果：CAR-DCs抑制了B16.HER2肿瘤的生长，并诱导了肿瘤浸润性细胞毒性CD8+T细胞的增殖与激活。PD-1检查点抑制剂进一步增强了抗肿瘤反应，并防止了T细胞衰竭。通过载体表达GM-CSF提高了抗肿瘤反应的持续性。
> 
> 结论：CAR-DCs可能是一种有效的实体瘤治疗策略，值得进一步研究。该方法依赖于DCs的抗原呈递能力及其在T细胞活化中的作用，可与检查点抑制机制结合，从而替代单克隆抗体治疗。

### 第二部分 AI 大师评价

本研究提出了一种创新性的嵌合抗原受体树突状细胞（CAR-DC）疗法，用于增强实体瘤，尤其是HER2阳性模型中的免疫应答。作者通过在小鼠模型中构建表达GM-CSF、CD40L及可溶性PD-1的CAR-DC，实现了对B16.HER2黑色素瘤生长的显著抑制，并促进了肿瘤浸润性CD8+T细胞的活化。该策略兼顾了抗原呈递与免疫检查点调控，显示出相较传统CAR-T疗法更适用于实体瘤的潜力。研究的主要创新在于CAR-DC的设计与多基因协同调控，但仍需进一步验证其临床可行性与安全性。

---

## 23. Netrin-1 通过 NEO1 促进胰腺肿瘤发生及神经支配

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41474982)
**期刊：** Cancer research
**PMID：** 41474982
**DOI：** 10.1158/0008-5472.CAN-25-2243

### 第一部分 原文与翻译

**英文原标题：** Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1.

> **英文摘要：**
> Nerves can regulate tumorigenesis and cancer progression. However, clarification of the role of axon guidance molecules in tumorigenesis, innervation, and metastasis is required to better understand the tumor-promoting functions of nerves. Using murine KrasG12D-mutant pancreatic organoids, we screened axon guidance molecules and identified netrin-1 upregulation. Netrin-1 was also upregulated in vivo during pancreatic tumorigenesis in humans and mice. Mutant KRAS and β-adrenergic signaling upregulated netrin-1 and its receptor NEO1 in epithelial cells in part through the MAPK pathway. Ex vivo culture of celiac ganglia showed that netrin-1 promoted the axonogenesis of sympathetic neurons through nerve NEO1. In the Pdx1-Cre;LSL-KrasG12D/+ model, knockout of Ntn1, which encodes netrin-1, decreased sympathetic innervation and the development of pancreatic intraepithelial neoplasia. Treatment of pancreatic tumor organoids with recombinant netrin-1 enhanced cell growth, epithelial-mesenchymal transition (EMT), and cancer stemness with the upregulation of ZEB1 and SOX9 through NEO1-mediated activation of focal adhesion kinase (FAK). In Pdx1-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ mice, Ntn1 knockout reduced innervation, FAK phosphorylation, and the features of EMT and stemness to extend mouse survival. In a liver metastasis model of pancreatic ductal adenocarcinoma (PDAC), treatment with a netrin-1-neutralizing antibody or tumoral knockout of Neo1 reduced ZEB1 and SOX9 and decreased tumor progression. In contrast, netrin-1 overexpression promoted innervation and the progression of PDAC liver metastasis. These data suggest that the netrin-1/NEO1 axis is a key regulator of PDAC progression, directly influencing cancer cell stemness and EMT, while indirectly promoting tumor growth through nerves. Inhibiting the netrin-1 pathway could represent a potential therapeutic approach for PDAC.

> **中文摘要：**
> 神经能够调控肿瘤发生与癌症进展。然而，要更好地理解神经促进肿瘤的功能，需要阐明轴突导向分子在肿瘤发生、神经支配及转移中的作用。利用携带 KrasG12D 突变的小鼠胰腺类器官，我们筛选了轴突导向分子，并发现 netrin-1 表达上调。在人类及小鼠的胰腺肿瘤发生过程中，体内亦观察到 netrin-1 上调。突变的 KRAS 和 β-肾上腺素能信号部分通过 MAPK 通路上调了上皮细胞中的 netrin-1 及其受体 NEO1。小鼠腹腔神经节的离体培养显示，netrin-1 可通过神经元 NEO1 促进交感神经元的轴突发生。在 Pdx1-Cre;LSL-KrasG12D/+ 模型中，敲除编码 netrin-1 的 Ntn1 基因，降低了交感神经支配及胰腺上皮内瘤变的发展。用重组 netrin-1 处理胰腺肿瘤类器官可通过 NEO1 介导的焦点黏附激酶（FAK）激活，上调 ZEB1 和 SOX9，增强细胞生长、上皮-间质转化（EMT）及癌症干性特征。在 Pdx1-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ 小鼠中，敲除 Ntn1 可降低神经支配、FAK 磷酸化及 EMT 与干性特征，从而延长小鼠生存期。在胰腺导管腺癌（PDAC）肝转移模型中，应用 netrin-1 中和抗体或敲除肿瘤内 Neo1 均可下调 ZEB1 和 SOX9，并减缓肿瘤进展。相反，netrin-1 的过表达促进了 PDAC 肝转移的神经支配和进展。这些结果表明，netrin-1/NEO1 轴是 PDAC 进展的关键调控因子，它既可直接影响癌细胞干性与 EMT，又可通过神经间接促进肿瘤生长。抑制 netrin-1 通路可能成为 PDAC 的潜在治疗策略。

### 第二部分 AI 大师评价

本研究揭示了 netrin-1/NEO1 通路在胰腺癌发生、神经支配及转移中的关键作用。作者通过胰腺类器官、小鼠模型及肝转移实验，系统阐明了 netrin-1 促进肿瘤生长与癌细胞干性及 EMT 的机制。研究显示其部分依赖 MAPK 及 FAK 信号通路，且影响交感神经的轴突发生。该工作创新性地将肿瘤-神经互作与肿瘤干性机制相连接，但仍需进一步探索其在人类 PDAC 临床中的治疗可行性。

---

## 24. 靶向STK17B激酶可激活铁死亡并抑制多发性骨髓瘤的耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40953235)
**期刊：** Blood
**PMID：** 40953235
**DOI：** 10.1182/blood.2025029950

### 第一部分 原文与翻译

**英文原标题：** Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma.

> **英文摘要：**
> The progression of multiple myeloma (MM), an incurable malignancy of plasma cells, is often associated with the suppression of ferroptosis, a type of cell death driven by iron-dependent lipid peroxidation. The mechanisms underlying this suppression remain largely unknown. Here, we identified serine/threonine kinase 17b (STK17B) kinase as a critical suppressor of ferroptosis in MM. Elevated levels of STK17B are associated with poor overall survival in patients with MM, and STK17B expression is significantly higher in relapsed vs newly diagnosed MM cases. We found that inhibiting STK17B in MM cells increased the labile iron pool, enhanced lipid peroxidation, and sensitized cells to conventional anti-MM therapies. Notably, an orally available, in-house-generated STK17B inhibitor induced ferroptosis and significantly reduced tumor growth in MM xenograft mouse models. Mechanistically, proximity labeling assay combined with the phospho-proteomic analysis identified 2 major regulators of iron uptake and transport as direct targets of STK17B: iron-responsive element binding protein 2 (IREB2), and heat shock protein family B member 1 (HSPB1). We demonstrated that STK17B phosphorylates critical regulatory sites on IREB2 (S157) and HSPB1 (S15), thereby modulating the balance between IREB2 and HSPB1 downstream effectors, proferroptotic transferrin receptor, and antiferroptotic ferritin heavy chain proteins. Furthermore, we demonstrated that STK17B indirectly maintains activating phosphorylation of STAT3, a ferroptosis suppressor and a major driver of MM pathobiology. Our findings uncovered a clinically relevant and targetable STK17B-pIREB2S157/pHSPB1S15 signaling axis that suppresses ferroptosis and contributes to drug resistance in MM.

> **中文摘要：**
> 多发性骨髓瘤（MM）是一种无法治愈的浆细胞恶性肿瘤，其进展常与铁死亡（由铁依赖的脂质过氧化驱动的一种细胞死亡方式）的抑制有关。导致这种抑制的机制在很大程度上仍不清楚。本研究鉴定出丝氨酸/苏氨酸激酶17B（STK17B）是MM中铁死亡的关键抑制因子。STK17B表达水平升高与MM患者较差的总体生存率相关，并且在复发病例中STK17B的表达显著高于新诊断病例。我们发现，在MM细胞中抑制STK17B可增加游离铁库、增强脂质过氧化，并使细胞对常规抗骨髓瘤疗法更加敏感。值得注意的是，一种可口服的本实验室开发的STK17B抑制剂能够诱导铁死亡，并在MM异种移植小鼠模型中显著抑制肿瘤生长。从机制上看，基于邻近标记检测结合磷酸蛋白质组学分析，发现铁摄取与转运的两种主要调节因子——铁响应元件结合蛋白2（IREB2）和热休克蛋白家族成员B1（HSPB1）——是STK17B的直接靶点。我们证实STK17B可在IREB2（S157）和HSPB1（S15）上磷酸化关键调控位点，从而调节IREB2与HSPB1下游效应器之间的平衡，即促铁死亡的转铁蛋白受体与抗铁死亡的铁蛋白重链蛋白。此外，我们还证明STK17B可间接维持STAT3（铁死亡抑制因子及MM发病机制的主要驱动因子）的活化性磷酸化。我们的研究揭示了一个具有临床相关性且可靶向的STK17B-pIREB2S157/pHSPB1S15信号轴，该轴通过抑制铁死亡而促进MM的耐药性。

### 第二部分 AI 大师评价

本研究揭示了STK17B作为调控多发性骨髓瘤中铁死亡的关键激酶，其抑制可促进铁死亡并增强化疗敏感性。研究采用蛋白质组学及功能实验，明确IREB2与HSPB1是STK17B的直接靶点，并建立了STK17B-IREB2/HSPB1-STAT3信号轴。研究创新之处在于首次阐明了STK17B在多发性骨髓瘤耐药形成中的机制性作用，同时提供了可药物化的干预靶点。尽管仍需进一步验证其临床可行性与安全性，但该工作为铁死亡相关治疗策略提供了新的方向。

---

速递结束，祝您工作愉快！